Binds Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator Specific For A Hematopoietic Cell (e.g., Interleukin, Interferon, Erythropoietin, Etc.) Patents (Class 530/388.23)
-
Patent number: 8324351Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.Type: GrantFiled: February 1, 2010Date of Patent: December 4, 2012Assignee: Xencor, Inc.Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
-
Patent number: 8318910Abstract: This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor ? and uses thereof.Type: GrantFiled: February 15, 2011Date of Patent: November 27, 2012Assignee: SanofiInventors: Daniel Caput, Pascual Ferrara, Patrick Laurent, Natalio Vita
-
Patent number: 8318168Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: GrantFiled: April 16, 2010Date of Patent: November 27, 2012Assignee: Morphotek, Inc.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
-
Patent number: 8318907Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.Type: GrantFiled: February 1, 2010Date of Patent: November 27, 2012Assignee: Xencor, Inc.Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
-
Publication number: 20120294870Abstract: Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.Type: ApplicationFiled: July 16, 2012Publication date: November 22, 2012Inventors: Vivian Takafuji, Xin Wei Wang, Edward J. Unsworth, Paul K. Goldsmith
-
Patent number: 8313747Abstract: An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-1?/CCL3, MIP-1?/CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.Type: GrantFiled: August 27, 2010Date of Patent: November 20, 2012Assignee: VLST CorporationInventors: Dan Allison, Carol Raport
-
Patent number: 8309692Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: GrantFiled: April 20, 2011Date of Patent: November 13, 2012Assignee: ZymoGenetics, Inc.Inventors: Cindy A. Sprecher, Scott R. Presnell, Zeren Gao, Theodore E. Whitmore, Joseph L. Kuijper, Mark F. Maurer
-
Publication number: 20120282269Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: November 2, 2011Publication date: November 8, 2012Applicant: Boehringer Ingelheim International GmbHInventors: Rachel Rebecca Barrett, Keith Canada, Katrina Mary Catron, Robert Copenhaver, Lee Edward Frego, Ernest Lee Raymond, Sanjaya Singh, Xiangyang Zhu
-
Patent number: 8303951Abstract: The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody.Type: GrantFiled: February 26, 2009Date of Patent: November 6, 2012Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Publication number: 20120275996Abstract: The present invention describes IL-1? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1?. Binding proteins of the invention have high affinity for IL-1? and neutralize IL-1? activity. A binding protein of the invention can be a full-length antibody or an IL-1?-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1? binding proteins of the invention are useful for detecting IL-1? and for inhibiting IL-1? activity, including in a human subject suffering from a disease or disorder in which IL-1? activity is detrimental.Type: ApplicationFiled: December 20, 2011Publication date: November 1, 2012Applicant: ABBOTT LABORATORIESInventor: Chung-ming Hsieh
-
Patent number: 8299219Abstract: An isolated polypeptide is provided, comprising an amino acid sequence being at least 88% homologous to SEQ ID NO: 15 (human) as determined by BlastP using default parameters, the isolated polypeptide being capable of promoting cell adhesion and/or cell homing.Type: GrantFiled: February 28, 2011Date of Patent: October 30, 2012Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Dafna Benayahu, Irena Shur
-
Patent number: 8298537Abstract: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.Type: GrantFiled: January 13, 2012Date of Patent: October 30, 2012Assignee: The Mathilda and Terence Kennedy Institute of Rheumatology TrustInventors: Marc Feldmann, Ravinder N. Maini
-
Publication number: 20120269820Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.Type: ApplicationFiled: June 8, 2012Publication date: October 25, 2012Inventors: Krzysztof Masternak, Olivier Leger
-
Publication number: 20120263718Abstract: Provided are methods and compositions for treating inflammatory autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. The interaction between DR3 and TL1A can be blocked by reducing expression of TL1A. The interaction between DR3 and TL1A can be blocked by administration of anti-DR3 antibodies. The interaction between DR3 and TL1A can be blocked by administration of anti-TL1A antibodies. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease (IBD).Type: ApplicationFiled: March 13, 2012Publication date: October 18, 2012Inventors: RICHARD M. SIEGEL, FRANCOISE MEYLAN, YUN-JEONG SONG
-
Patent number: 8287869Abstract: The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23). The invention further concerns the use of IL-23 antagonists in the treatment of inflammatory diseases characterized by the presence of elevated levels of IL-17. IL-23 antagonists include, without limitation, antibodies specifically binding to a subunit or IL-17 or an IL-17 receptor. The invention additionally concerns induction of IL-7 production by using an IL-23 agonist.Type: GrantFiled: January 7, 2009Date of Patent: October 16, 2012Assignee: Genentech, Inc.Inventor: Austin L. Gurney
-
Patent number: 8283131Abstract: The present invention provides for the in vitro establishing of a prognosis for a subject in severe sepsis with at least two organ failures or in septic shock with at least two organ failures. Embodiments of the invention comprise the steps of measuring the level of the S100A8/A9 complex from a biological sample from a subject, and comparing the measured level to a predetermined threshold in which the measured level of the S100A8/A9 complex above the predetermined threshold is indicative of a bad prognosis and a measured level of the S100A8/A9 complex below the predetermined threshold is indicative of a good prognosis.Type: GrantFiled: October 28, 2008Date of Patent: October 9, 2012Assignee: Assistance Publique-Hopitaux de ParisInventors: Didier Payen De La Garanderie, Anne-Claire Lukaszewicz
-
Patent number: 8283451Abstract: The present invention relates to a method of predicting pre-eclampsia (PE). The present invention also relates to a diagnostic kit for performing a method of predicting PE. In particular, the method determining the level of two or more markers selected from placenta growth factor (PlGF), plasminogen activator inhibitor-1 (PAI-1), plasminogen activator inhibitor-2 (PAI-2) and leptin.Type: GrantFiled: August 19, 2011Date of Patent: October 9, 2012Assignee: Perkinelmer Las, Inc.Inventors: Lucilla Poston, Paul Townsend Seed, Beverley Jane Hunt, Lucy Charlotte Chappell
-
Patent number: 8282922Abstract: This invention relates to a novel use of IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1? ligand-IL-1 receptor interaction, IL-1? antibodies or IL-1 receptor antibodies, e.g. IL-1? binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1? binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1? ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.Type: GrantFiled: May 28, 2008Date of Patent: October 9, 2012Assignee: Novartis AGInventors: Hermann Gram, Thomas Jung
-
Publication number: 20120251550Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.Type: ApplicationFiled: September 2, 2011Publication date: October 4, 2012Applicant: Abbott Biotechnology Ltd.Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
-
Patent number: 8277804Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.Type: GrantFiled: November 24, 2009Date of Patent: October 2, 2012Assignee: Alderbio Holdings LLCInventor: Jeffrey T. L. Smith
-
Patent number: 8278099Abstract: Isolated thrombopoietin (TPO), isolated DNA encoding TPO, and recombinant or synthetic methods of preparing and purifying TPO are disclosed. Various forms of TPO are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.Type: GrantFiled: May 3, 1995Date of Patent: October 2, 2012Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. de Sauvage
-
Publication number: 20120244148Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-? monoclonal antibodies with broad reactivity against various IFN-? subtypes. The invention further relates to the use of such anti-IFN-? antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-?, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).Type: ApplicationFiled: May 21, 2012Publication date: September 27, 2012Applicant: Genentech, Inc.Inventors: Anan Chuntharapai, Jin K. Kim, Leonard G. Presta, Timothy Stewart
-
Patent number: 8273350Abstract: An IL-1? binding molecule, in particular an antibody to human IL-1?, especially a human antibody to human IL-1? is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.Type: GrantFiled: June 29, 2011Date of Patent: September 25, 2012Assignee: Novartis AGInventors: Hermann Gram, Franco E Di Padova
-
Publication number: 20120230911Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.Type: ApplicationFiled: December 8, 2011Publication date: September 13, 2012Applicant: ABBOTT LABORATORIESInventors: Chung-ming HSIEH, Carrie L. GOOGREAU, Sahana BOSE, Achim MOELLER, Tariq GHAYUR
-
Publication number: 20120231011Abstract: The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.Type: ApplicationFiled: August 27, 2010Publication date: September 13, 2012Applicants: Apexigen Inc., Jiangsu Simcere Pharmaceutical R&D Co., LtdInventors: Pierre Li, Yaohuang ke, Yongke Zhang, Weimin Zhu, Guoliang Yu, Fanxin Ma, Xin Fan
-
Patent number: 8263748Abstract: The present invention provides lyophilized formulations of antibodies, such as antibodies that specifically bind to human interleukin-23 p19 (IL-23p19), or antigen binding fragments thereof.Type: GrantFiled: August 25, 2009Date of Patent: September 11, 2012Assignee: Schering CorporationInventors: Xuhong Li, Ramesh S. Kashi, Aniket Badkar
-
Patent number: 8263746Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.Type: GrantFiled: February 7, 2005Date of Patent: September 11, 2012Assignee: Morphosys AGInventors: Michael Tesar, Ute Jager
-
Patent number: 8258267Abstract: The invention relates to fully human antibodies, and fragments thereof, that bind to interferon-inducible-protein-10 (IP-IO, CXCL1O), thereby modulating the interaction between IP-IO and its receptor, CXCR3, and/or modulating the biological activities of IP-IO. The invention also relates to the use of such anti-IP-10 antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.Type: GrantFiled: February 28, 2008Date of Patent: September 4, 2012Assignee: NovImmune S.A.Inventors: Nicolas Fischer, Marie Kosco-Vilbois, Olivier Leger
-
Patent number: 8257704Abstract: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.Type: GrantFiled: June 21, 2011Date of Patent: September 4, 2012Assignee: Eli Lilly and CompanyInventors: Andrew Ihor Korytko, David Matthew Marquis, Eric Michael Smith, Barbara Anne Swanson
-
Patent number: 8258266Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: GrantFiled: May 27, 2009Date of Patent: September 4, 2012Assignee: Medarex, Inc.Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David B. Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
-
Patent number: 8252905Abstract: A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.Type: GrantFiled: June 5, 2006Date of Patent: August 28, 2012Assignee: Mochida Pharmaceutical Co., Ltd.Inventors: Shoji Furusako, Kazuyuki Nakayama, Yoshitaka Hosaka, Tetsushi Kawahara, Masaki Nakamura, Takashi Takeuchi
-
Patent number: 8252286Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.Type: GrantFiled: November 25, 2008Date of Patent: August 28, 2012Assignee: Alderbio Holdings LLCInventor: Jeffrey T. L. Smith
-
Publication number: 20120214971Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.Type: ApplicationFiled: November 30, 2011Publication date: August 23, 2012Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
-
Patent number: 8246953Abstract: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis.Type: GrantFiled: November 11, 2010Date of Patent: August 21, 2012Assignee: Novartis AGInventors: Michaela Kniessel, Christine Halleux, Shou-Ih Hu, Beate Diefenbach-Streiber, Josef Prassler
-
Patent number: 8241899Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.Type: GrantFiled: November 14, 2008Date of Patent: August 14, 2012Assignee: Centocor, Inc.Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
-
Patent number: 8242074Abstract: The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality.Type: GrantFiled: September 14, 2009Date of Patent: August 14, 2012Assignee: XBiotech, Inc.Inventor: John Simard
-
Patent number: 8241900Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.Type: GrantFiled: April 13, 1995Date of Patent: August 14, 2012Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. De Sauvage
-
Patent number: 8241629Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: GrantFiled: December 17, 2010Date of Patent: August 14, 2012Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Publication number: 20120201826Abstract: The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.Type: ApplicationFiled: August 11, 2011Publication date: August 9, 2012Inventors: Nicolas Fischer, Marie Kosco-Vilbois, Francois Mach
-
Patent number: 8231876Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.Type: GrantFiled: September 15, 2010Date of Patent: July 31, 2012Assignee: Abbott Biotechnology Ltd.Inventors: Min M. Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
-
Patent number: 8231874Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.Type: GrantFiled: July 28, 2011Date of Patent: July 31, 2012Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
-
Patent number: 8231873Abstract: The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody.Type: GrantFiled: August 27, 2010Date of Patent: July 31, 2012Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Publication number: 20120190829Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders.Type: ApplicationFiled: April 3, 2012Publication date: July 26, 2012Applicant: AMGEN INC.Inventors: Michael R. COMEAU, James F. SMOTHERS, Bo-Rin P. YOON, Christopher MEHLIN
-
Patent number: 8226948Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: GrantFiled: January 11, 2012Date of Patent: July 24, 2012Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Patent number: 8227575Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: GrantFiled: November 25, 2009Date of Patent: July 24, 2012Assignee: ZymoGenetics, Inc.Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
-
Patent number: 8226611Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.Type: GrantFiled: October 27, 2011Date of Patent: July 24, 2012Assignees: Janssen Biotech, Inc., Applied Molecular EvolutionInventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
-
Patent number: 8221749Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: GrantFiled: July 29, 2011Date of Patent: July 17, 2012Assignee: Amgen Inc.Inventors: Thomas C. Boone, Jonathan D. Oliner
-
Publication number: 20120177655Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: ApplicationFiled: January 11, 2012Publication date: July 12, 2012Applicant: ZYMOGENETICS, INC.Inventors: Stephen R. JASPERS, Mark W. RIXON, Stacey R. DILLON, Frederick J. RAMSDELL, Cecile M. KREJSA, Eugene C. YI
-
Patent number: 8216576Abstract: The invention provides an isolated protein which is a member of the TNF ligand superfamily and comprising: i) a polypeptide having the amino acid sequence of FIG. 1; or ii) a variant of the polypeptide of i).Type: GrantFiled: May 8, 2007Date of Patent: July 10, 2012Assignee: Glaxo Group LimitedInventors: Stuart Neville Farrow, Allard Kaptein, Jeremy David Alistair Kitson, Alison J. Winder
-
Patent number: RE43672Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.Type: GrantFiled: July 8, 2011Date of Patent: September 18, 2012Assignees: Janssen Biotech, Inc., Applied Molecular EvolutionInventors: Yan Chan, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot